Retatrutide

Retatrutide is a novel, investigational single-molecule peptide agonist that targets three key metabolic receptors—GLP-1, GIP, and Glucagon—to promote weight loss, improve glucose control, and enhance metabolic function.

Structure

Synthetic 39–amino acid linear peptide.
Engineered to provide balanced agonism at the GLP-1, GIP, and Glucagon receptors.

Mechanism of Action

• GLP-1 Receptor Agonism: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety, reducing calorie intake.
• GIP Receptor Agonism: Enhances insulin secretion and may improve fat metabolism, contributing to weight loss and improved insulin sensitivity.
• Glucagon Receptor Agonism: Increases energy expenditure and hepatic fat metabolism, counteracting metabolic slowdown from calorie restriction, while GLP-1 activity prevents hyperglycemia.
  
  Indications
  (Preclinical and early-stage studies) :

Chronic Weight Management (obesity)
Type 2 Diabetes Mellitus